112 related articles for article (PubMed ID: 32231715)
21. Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib.
Wang Y; Liu S; Feng A; Luo H; Hu J; Wang K; Dong W
Front Oncol; 2021; 11():727312. PubMed ID: 34745948
[TBL] [Abstract][Full Text] [Related]
22. A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy.
Cong J; Zhang Y; Xue Y; Zhang C; Xu M; Liu D; Zhang R; Zhu H
Front Microbiol; 2020; 11():583525. PubMed ID: 33240237
[TBL] [Abstract][Full Text] [Related]
23. Improving the tolerability of osimertinib by identifying its toxic limit.
Agema BC; Veerman GDM; Steendam CMJ; Lanser DAC; Preijers T; van der Leest C; Koch BCP; Dingemans AC; Mathijssen RHJ; Koolen SLW
Ther Adv Med Oncol; 2022; 14():17588359221103212. PubMed ID: 35677320
[TBL] [Abstract][Full Text] [Related]
24. Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9789654. PubMed ID: 37476338
[TBL] [Abstract][Full Text] [Related]
25. The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.
Gil HI; Um SW
J Thorac Dis; 2020 Mar; 12(3):153-155. PubMed ID: 32274079
[No Abstract] [Full Text] [Related]
26. Impact of performance status and age on osimertinib efficacy in patients with
Lamberti G; Andrini E; Ricciuti B
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1831-S1834. PubMed ID: 31632761
[No Abstract] [Full Text] [Related]
27. Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis.
Ma Q; Wang J; Ren Y; Meng F; Zeng L
J Oncol; 2020; 2020():6249829. PubMed ID: 32256584
[TBL] [Abstract][Full Text] [Related]
28. The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.
Butterworth S; Cross DAE; Finlay MRV; Ward RA; Waring MJ
Medchemcomm; 2017 May; 8(5):820-822. PubMed ID: 30108799
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M.
Zhang X
Glob Med Genet; 2021 Dec; 8(4):133-134. PubMed ID: 34877569
[No Abstract] [Full Text] [Related]
30. Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer.
Li S; Segal EM
J Adv Pract Oncol; 2017 Mar; 8(2):196-201. PubMed ID: 29900027
[No Abstract] [Full Text] [Related]
31. HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.
Yamaoka T; Tsurutani J; Sagara H; Ohmori T
Transl Lung Cancer Res; 2020 Oct; 9(5):2178-2183. PubMed ID: 33209639
[No Abstract] [Full Text] [Related]
32. Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer.
Noronha V; Majumdar S; Joshi A; Patil V; Trivedi V; Chougule A; Prabhash K
South Asian J Cancer; 2017; 6(4):143. PubMed ID: 29404287
[No Abstract] [Full Text] [Related]
33. Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers.
Ebi H; Boikos S; Faber AC
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1844-S1846. PubMed ID: 31632765
[No Abstract] [Full Text] [Related]
34. Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?
Malapelle U; Rossi A; Bria E
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1837-S1840. PubMed ID: 31632763
[No Abstract] [Full Text] [Related]
35. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum.
Medicine (Baltimore); 2019 Aug; 98(32):e16824. PubMed ID: 31393415
[No Abstract] [Full Text] [Related]
36. Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial.
Ito K; Hataji O
J Thorac Dis; 2018 Sep; 10(Suppl 26):S3071-S3077. PubMed ID: 30430025
[No Abstract] [Full Text] [Related]
37. Does the natural product, honokiol, have value in the battle against osimertinib resistance?
Vallega KA; Sun SY
Oncoscience; 2020 Sep; 7(9-10):73-75. PubMed ID: 33195738
[No Abstract] [Full Text] [Related]
38. Osimertinib in first line setting: preventive or delayed T790M occurrence?
Sun H; Wu Y
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S187-S190. PubMed ID: 30393597
[No Abstract] [Full Text] [Related]
39. Finding chinks in the osimertinib resistance armor.
Leal JL; Solomon B; John T
Transl Lung Cancer Res; 2020 Oct; 9(5):2173-2177. PubMed ID: 33209638
[No Abstract] [Full Text] [Related]
40. Does osimertinib treatment discriminate young patients?
Ji C; Zhong C; Sun SY
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1852-S1854. PubMed ID: 31632767
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
